Examination of the efficacy of anamorelin in chemotherapy for gastric cancer patients with cachexia - Examination of the efficacy of anamorelin in chemotherapy for gastric cancer patients with cachexia

Tokyo Metropolitan Tama Medical Center Department of Surgery0 个研究点目标入组 10 人开始时间: 2021年11月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients with gastrointestinal disorders who have difficulty in taking food orally or who require gastrointestinal rest 2. Patients with congestive heart failure, underlying heart disease (valvular disease, cardiomyopathy, etc.), history of myocardial infarction or angina, conduction system disorder, risk of QT interval prolongation or a history thereof 3. Patients with a history of administration of anthracyclines 4. Patients receiving strong CYP3A4 inhibitors (drugs containing clarislomycin, indinavir, itraconazole, nelfinavir, saquinavir, telaprevir, voriconazole, ritonavir, cobicistat) 5. Patients who have confirmed ascites in an amount exceeding the physiological range 6. Patients with confirmed pleural effusion 7. Patients with moderate or higher liver dysfunction (Child-Pugh classifications B and C) 8. Patients judged by the attending physician to be inappropriate for participation in the study

发起方

Tokyo Metropolitan Tama Medical Center Department of Surgery